Estradiol/norethisterone continuous transdermal - Elan Pharma

Drug Profile

Estradiol/norethisterone continuous transdermal - Elan Pharma

Latest Information Update: 15 May 2006

Price : $50

At a glance

  • Originator Elan Pharma International
  • Developer Pfizer
  • Class Estradiol congeners; Estrenes; Hormonal contraceptives; Hormonal replacements; Norpregnenes; Oral contraceptives; Small molecules
  • Mechanism of Action Estrogen receptor agonists; Progesterone receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Marketed Menopausal syndrome

Most Recent Events

  • 16 Apr 2003 Pharmacia Corporation has been acquired by, and merged into, Pfizer
  • 05 Apr 2000 Monsanto has merged with Pharmacia & Upjohn to form Pharmacia Corporation
  • 01 Feb 2000 Ethical Holdings is now called Amarin Corporation
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top